TABLE 2.

Demographic, virologic, and biochemical characteristics of patients with acute HCV infection^a

Patient	Genotype	Age (yr)	Sex	1st time point			2nd time point			3rd time point			Outcome
				Wk from clinical presentation	AST/ALT	HCV RNA (copies/ml)	Wk from clinical presentation	HCV RNA (copies/ml)	AST/ALT	Wk from clinical presentation	HCV RNA (copies/ml)	AST/ALT
1C	1b	58	F	1	177/875	<2,500	14	<2,500	19/17	25	<2,500	13/11	Self-limited
2C	3a	26	M	5	13/69	<2,500	16b	324,449	23/100	30	305,202	20/63	Chronic
3C	3a	25	M	1	123/356	<2,500	9	<2,500	23/31	29	<2,500	28/32	Self-limited
4C	1a	34	M	2	125/336	71,891	12	9,150	29/182	40	171,545	33/55	Chronic
5C	3a	27	F	1	1,120/2,190	ND	14b	ND	18/30	30	184,356c	233/388	Chronic
6C	1b	33	M	2	52/277	2,533	13	398,209	44/83	26b	2,263,736	44/145	Chronic
7C	3a	30	M	1	50/269	ND	16b	<2,500	32/27	80	<2,500	17/9	Self-limited

^aPatients were studied at three different time points of the follow-up. ND, not determined; F, female; M, male. The lower limit of detection for HCV RNA is 2,500 copies/ml.

^bNo immunological analysis performed in parallel.

^cViremia evaluated at a later time point relative to immunological analysis.